Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAN-NEURO-07
- Development stage
- Preclinical
- Lead developer
- Kantify
- Modality
- Small Molecules
01
Overview
KAN-NEURO-07 is a small molecule calcium channel modulator currently in preclinical development for the treatment of essential tremor. Discovered and developed by Kantify using its proprietary Sapian AI platform, the program is being advanced in collaboration with researchers from INSERM (specifically the Institut des Neurosciences de Montpellier and the Institut de Génomique Fonctionnelle). The drug is designed to target calcium channel activity to address the neurological dysfunction underlying essential tremor, a common movement disorder characterized by involuntary rhythmic shaking. As of early 2024, the program remains in the preclinical validation stage.
02
Targets
CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on KAN-NEURO-07.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAN-NEURO-07.